Arbutus Biopharma Corp
Arbutus Biopharma Corp (ABUS) Implied Volatility Current
ABUS's 30 day implied volatility is 219.37%, with an IV Rank of 83.33%. This is a high IV Rank versus the past year, meaning Arbutus Biopharma Corp options are relatively expensive and currently favor sellers. ABUS's 30 day historical volatility sits at 45.19%, which means implied volatility is running 174.18 points above historical volatility, as of Nov 20, 2026.
Read more
Tracking ABUS implied volatility helps you spot when Arbutus Biopharma Corp options are historically cheap or expensive, and where the best trades are hiding. When ABUS IV rises, premiums increase and sellers get more attractive pricing, and when it drops, buyers find cheaper contracts. Use our scanner to monitor ABUS implied volatility current levels in real time and filter for high probability trades.
Implied volatility is derived from option prices and represents the annualized expected move of a stock. Tracking ABUS IV rank helps you see whether ABUS's implied volatility is historically high or low, since IV rank compares today's reading against the past year's range. A high rank signals relatively expensive premiums and tends to favor sellers, a low rank signals relatively cheap premiums and tends to favor buyers.
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19.
Implied Volatility
IV is highly elevated. Premiums are expensive, strongly favoring sellers.
As of Nov 20, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →